[{"id":"1f03d618-be31-41e9-b5f3-97ec0ce2a2ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT06580002","created_at":"2025-02-26T10:15:43.559Z","updated_at":"2025-02-26T10:15:43.559Z","phase":"Phase 2","brief_title":"Repurposing Riluzole for Cancer-Related Cognitive Impairment: a Pilot Trial","source_id_and_acronym":"NCT06580002","lead_sponsor":"University of California, Irvine","biomarkers":" BDNF","pipe":"","alterations":" ","tags":["BDNF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e riluzole"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 12/02/2024","start_date":" 12/02/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-12-06"},{"id":"50c58012-9b92-4096-929a-64264a8757b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04761614","created_at":"2024-05-16T20:32:16.261Z","updated_at":"2024-07-02T16:35:03.341Z","phase":"Phase 1","brief_title":"Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04761614","lead_sponsor":"Ning Jin","biomarkers":" IFNG • IL6 • CRP • FCGRT • LIF","pipe":"","alterations":" ","tags":["IFNG • IL6 • CRP • FCGRT • LIF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • oxaliplatin • leucovorin calcium • fluorouracil topical • riluzole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 04/02/2021","start_date":" 04/02/2021","primary_txt":" Primary completion: 05/06/2023","primary_completion_date":" 05/06/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-16"},{"id":"f374dc4d-c613-437c-8a29-943b1442e3ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT01303341","created_at":"2021-01-18T05:18:01.764Z","updated_at":"2024-07-02T16:35:13.428Z","phase":"Phase 1","brief_title":"Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma","source_id_and_acronym":"NCT01303341","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression • MCL1 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • riluzole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 02/18/2011","start_date":" 02/18/2011","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 09/09/2024","study_completion_date":" 09/09/2024","last_update_posted":"2024-03-21"},{"id":"63328e57-2431-41ab-b27a-48549dfada08","acronym":"","url":"https://clinicaltrials.gov/study/NCT02796755","created_at":"2021-01-18T13:43:17.215Z","updated_at":"2024-07-02T16:36:31.957Z","phase":"Phase 4","brief_title":"Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation","source_id_and_acronym":"NCT02796755","lead_sponsor":"Emory University","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e riluzole"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 10/24/2019","primary_completion_date":" 10/24/2019","study_txt":" Completion: 10/24/2019","study_completion_date":" 10/24/2019","last_update_posted":"2021-04-14"}]